Společnost uniQure oznamuje aktuální informace o klinických studiích fáze I/II genové terapie AMT-130 pro léčbu Huntingtonovy choroby

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients Číst více...

cs_CZCzech